CeriBell, Inc. (NASDAQ:CBLL) Receives Average Recommendation of "Buy" from Brokerages

Key Points

• CeriBell, Inc. has received a consensus rating of "Buy" from eight brokerage firms, with an average 12-month price target of $32.14.
• The company's most recent quarterly earnings report showed earnings of ($0.38) per share, exceeding analyst estimates and generating a revenue of $21.20 million.
• Insiders have sold a significant number of shares recently, with CEO Xingjuan Chao selling 25,000 shares, which indicates potential changes in management confidence in the stock.

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) has been assigned an average recommendation of "Buy" from the eight research firms that are presently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $32.1429.

Separately, BTIG Research started coverage on shares of CeriBell in a research note on Tuesday, June 24th. They set a "buy" rating and a $30.00 target price for the company.

Insider Activity

In other news, CEO Xingjuan Chao sold 25,000 shares of CeriBell stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.00, for a total transaction of $425,000.00. Following the sale, the chief executive officer owned 776,022 shares of the company's stock, valued at approximately $13,192,374. The trade was a 3.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Rebecca B. Robertson sold 20,000 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $17.14, for a total value of $342,800.00. Following the completion of the transaction, the director directly owned 28,675 shares of the company's stock, valued at $491,489.50. This trade represents a 41.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 113,633 shares of company stock valued at $1,965,261 in the last 90 days. Insiders own 20.10% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. FMR LLC acquired a new position in shares of CeriBell during the fourth quarter valued at $128,120,000. TPG GP A LLC bought a new stake in shares of CeriBell during the 4th quarter worth about $102,677,000. Red Tree Management LLC acquired a new stake in shares of CeriBell in the 4th quarter worth approximately $57,083,000. Yu Fan bought a new position in shares of CeriBell in the fourth quarter valued at approximately $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd acquired a new position in shares of CeriBell during the fourth quarter valued at approximately $28,160,000.

CeriBell Stock Down 1.6%

Shares of CBLL stock traded down $0.20 during mid-day trading on Thursday, reaching $12.58. 510,264 shares of the company were exchanged, compared to its average volume of 272,879. The company has a debt-to-equity ratio of 0.11, a quick ratio of 16.81 and a current ratio of 13.31. The business's 50 day simple moving average is $16.77 and its 200 day simple moving average is $18.61. The company has a market capitalization of $454.64 million and a P/E ratio of -4.21. CeriBell has a fifty-two week low of $10.01 and a fifty-two week high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.02. CeriBell had a negative net margin of 63.83% and a negative return on equity of 48.42%. The company had revenue of $21.20 million during the quarter, compared to analyst estimates of $20.52 million. Research analysts predict that CeriBell will post -2.46 earnings per share for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.